Pluripotency factors regulate definitive endoderm specification through eomesodermin

  1. Ludovic Vallier1,5,6
  1. 1Laboratory for Regenerative Medicine, University of Cambridge, Cambridge CB2 0SZ, United Kingdom;
  2. 2Institute of Medical Biology, A*STAR (Agency for Science, Technology, and Research), Singapore 138648;
  3. 3Renal Department, Centre for Clinical Research, University Medical Centre, 79106 Freiburg, Germany;
  4. 4Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom
    1. 5 These authors contributed equally to this work.

    Abstract

    Understanding the molecular mechanisms controlling early cell fate decisions in mammals is a major objective toward the development of robust methods for the differentiation of human pluripotent stem cells into clinically relevant cell types. Here, we used human embryonic stem cells and mouse epiblast stem cells to study specification of definitive endoderm in vitro. Using a combination of whole-genome expression and chromatin immunoprecipitation (ChIP) deep sequencing (ChIP-seq) analyses, we established an hierarchy of transcription factors regulating endoderm specification. Importantly, the pluripotency factors NANOG, OCT4, and SOX2 have an essential function in this network by actively directing differentiation. Indeed, these transcription factors control the expression of EOMESODERMIN (EOMES), which marks the onset of endoderm specification. In turn, EOMES interacts with SMAD2/3 to initiate the transcriptional network governing endoderm formation. Together, these results provide for the first time a comprehensive molecular model connecting the transition from pluripotency to endoderm specification during mammalian development.

    Keywords

    Footnotes

    • Received October 25, 2010.
    • Accepted December 20, 2010.
    | Table of Contents

    Life Science Alliance